Español
PDFs by language
Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Live Chat available weekdays, 7:00 am - 6:30 pm CT
Call us at 1-800-227-2345
Available any time of day or night
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Immunotherapy is a type of cancer treatment that helps the immune system find and attack cancer cells. There are many different types of immunotherapy, and they work in different ways. One type, called immune checkpoint inhibitors, can be used to treat advanced ovarian cancers that have certain features.
The immune system uses “checkpoints” to help keep it from attacking normal cells. These checkpoints are proteins on immune cells that are turned on or off to start an immune response. Cancer cells sometimes use these checkpoints to hide from the immune system. Immune checkpoint inhibitors are drugs that target these checkpoints to help the immune system find and attack cancer cells.
Pembrolizumab (Keytruda) and dostarlimab (Jemperli) target PD-1, a protein on certain immune cells called T cells that normally prevents them from attacking healthy cells. Blocking PD-1 boosts the immune response against cancer, which can shrink some tumors or slow their growth. These drugs may be used for advanced ovarian cancers that:
Pembrolizumab can also be used for advanced ovarian cancer with a high tumor mutational burden (TMB-H), meaning the cancer cells have many gene mutations.
These treatments are given as an intravenous (IV) infusion every 3 weeks.
Side effects of these drugs can include
Less often, more serious side effects occur, including:
It’s very important to report any new side effects to your cancer care team as soon as possible. If serious side effects do occur, treatment may need to be stopped and you may need high doses of corticosteroids to suppress your immune system.
To learn more about how drugs that work on the immune system are used to treat cancer, see Cancer Immunotherapy.
To learn about some of the side effects listed here and how to manage them, see Managing Cancer-related Side Effects.
Developed by the American Cancer Society medical and editorial content team with medical review and contribution by the American Society of Clinical Oncology (ASCO).
Berton D, Banerjee S, Curigliano G, et al. Antitumor activity of dostarlimab in patients with mismatch repair–deficient (dMMR) tumors: a combined analysis of 2 cohorts in the GARNET study [abstract]. J Clin Oncol 2021;39(Suppl):Abstract 2564.
Coleman RL, Liu J, Matsuo K, Thaker PH, Weston SN, and Sood Ak. Chapter 86: Carcinoma of the Ovaries and Fallopian Tubes. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 6th ed. Philadelphia, Pa. Elsevier: 2020.
Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409-413.
National Comprehensive Cancer Network (NCCN)--Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. V2.2025. Accessed May 20, 2025 from https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf
Last Revised: August 8, 2024
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.